CAH

Cardinal Health Inc. presents a distinctive fundamental profile among healthcare distributors, with systematic screening highlighting an exceptionally high return on equity of 37.17% contrasted against elevated financial leverage and modest operational margins. Trading at $199.77 with a market capitalization of $45.7 billion, CAH demonstrates defensive characteristics through its beta of 0.54, suggesting lower volatility relative to broader market movements.

The company's financial structure reveals substantial scale efficiency. Revenue growth of 12.88% year-over-year substantially exceeds EPS expansion of 2.26%, indicating margin compression within the distribution model. The price-to-sales ratio of 0.18 reflects the capital-intensive, low-margin nature of pharmaceutical wholesale operations, where net profitability stands at 0.62% and operating margin registers 0.92%. Despite thin margins, CAH generates a price-to-book multiple of 9.25 supported by that 37.17% ROE, demonstrating efficient capital deployment within constrained equity.

Key considerations from fundamental screening:

• Capital efficiency advantage: The 37.17% ROE significantly outpaces typical distribution sector benchmarks, enabled by a debt-to-equity ratio of 3.48 that amplifies returns on limited equity base
• Defensive positioning: Beta of 0.54 and healthcare sector exposure provide portfolio stability characteristics during market volatility
• Liquidity constraint: Current ratio of 0.94 falls below the 1.0 threshold, indicating working capital management requires ongoing attention
• Leverage risk: The 3.48 debt-to-equity ratio magnifies both returns and financial vulnerability during margin pressure periods

Relative to peers McKesson (MCK) and Cencora (COR), Cardinal Health's valuation metrics and operational scale position the company within the top tier of pharmaceutical distribution networks, though margin profiles remain compressed across the competitive landscape.